Benefits of GIK in Cardiac Surgery Patients

• Status: Active, not recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of modified glucose - insulin - potassium (GIK) therapy in cardiac surgery patients undergoing cardiopulmonary bypass (CPB).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xijing Hospital
• Treatments: Insulin; Insulin, Globin Zinc; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Between 18 and 70 years of age

• Elective cardiac surgery with first time cardiopulmonary bypass

• Left ventricular ejection fraction(LVEF) ≥ 30%

• Informed agreement signed

Exclusion Criteria:

• Previous cardiac surgery

• Emergent surgery

• Cardiac surgery without the use of cardiopulmonary bypass

• Diabetes mellitus

• Severe renal insufficiency

• Severe respiratory insufficiency

• Serious preoperative illness (sepsis, active infection or active malignancy requiring treatment)

• Pregnant woman or positive pregnancy test

• History of drug abuse

• Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion

• Enrollment in another clinical study

• Lack of informed consent